ArticleDiabetes technology & therapeutics2022

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study.

Satish K Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.